Skip to content

Business & MarketsDeveloping

Moderna and Merck shares fall after leak of melanoma vaccine trial data

By

Coverage spectrum

Covered by 4 outlets, mostly center (75%).

5 articles in total. The spectrum counts each outlet once and leaves opinion out. How we measure bias

Shares of Moderna and Merck fell after data on their personalized melanoma vaccine leaked before the full Phase 3 results were released. The Financial Times reports that the vaccine cut the risk of recurrence or death by 58 percent. CNBC reports that the full data appeared positive against Wall Street expectations. The Financial Times says the results missed those expectations, and Bloomberg says the data did not prove a new era of cancer treatment has arrived. MarketWatch reported that the companies were expected to present the data at a medical conference.

Headline and summary written by Mantle’s AI from the coverage below, under published rules. How this works

What happened

Key points

Each point shows who reports it, from Far Left to Far Right.

  1. Moderna and Merck were expected to present Phase 3 data on their experimental cancer vaccine at a medical conference.

    One outletMarketWatch· Center

  2. Data on the personalized melanoma vaccine leaked before its full release, and Moderna and Merck shares fell.

    Reported byLeft1Center3See the outletsHide the outlets
    Left
    Bloomberg
    Center
    MarketWatch, CNBC, Financial Times

  3. The Financial Times reports that the vaccine cut the risk of recurrence or death by 58 percent.

    One outletFinancial Times· Center

  4. Against Wall Street expectations the full data appeared positive, but the shares still fell.

    One outletCNBC· Center

What is contested

Where accounts differ

Points the coverage does not agree on, and who says what.

  • The melanoma vaccine results were positive.

    CNBC says the full data appeared positive against Wall Street expectations. The Financial Times says the results missed those expectations. Bloomberg says the data were not enough to prove a new era of cancer treatment has arrived.

How each side tells it

Compare views

Every side present reports that Moderna and Merck shares fell after a leak of Phase 3 data on their melanoma vaccine. Center outlets stress positive results measured against high Wall Street expectations, while the left outlet says the data did not prove a new era of cancer treatment.

  • the left

    1 outlet

    The one left-side report, from Bloomberg, leads with the share drop and says the data did not prove a new era of cancer treatment has arrived.

    Moderna, Merck Fall After Melanoma Data Leak
    BloombergLeftAll left-leaning headlines

  • the center

    3 outlets

    Center outlets lead with the leak and the share drop, and frame the trial results against high Wall Street expectations.

    Moderna shares sink after leaked cancer data missed expectations
    Financial TimesCenterAll center headlines

  • the right

    No coverage yet

    No right-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.

The words they chose

Language to notice

Words that carry a judgement beyond the facts. Tap a highlighted word anywhere on the page to see why.

  • Left0

    No loaded words in its own voice.

  • Center1

    lofty expectations

  • Right

    Has not covered this story.

In the outlets’ own words

  • Loaded modifier

    lofty expectationsMore neutral: high expectations

    The word lofty judges Wall Street’s expectations as too high without citing a source for that judgement.

    …cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations

    Used byFinancial Times (Center)

See the full language guide

See for yourself

Side by side

What each side leads with and what it leaves out. Open a side to read its headlines.

From the left

1 outlet

Leads with

  • share drop after leak
  • data not proof of a new era
  • leaked melanoma data

Leaves out

  • 58 percent reduction in risk of recurrence or death

Reported by other sides, not found in this side’s coverage.

See the headline from the leftHide the headlines
  • BloombergLeft

    Moderna, Merck Fall After Melanoma Data Leak

    Moderna and Merck shares plummeted after data on the companies' personalized melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. Michelle Fay Cortez has more on "Bloomberg The Close." (Source: Bloomberg)

    Read at Bloomberg (opens in a new tab)

From the center

3 outlets

Leads with

  • leak and stock drop
  • results versus Wall Street expectations
  • positive trial results
See the 3 headlines from the centerHide the headlines

From the right

0 outlets

No right-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.

Articles you open from here build My Mix, a private picture of how your reading spreads across the spectrum, kept on this device. What is My Mix?

The left is Far Left and Left together. The right is Right and Far Right together. Every outlet keeps its own five-point rating.

Who reported it when

How the coverage built up

  • Left

    1 day 5 hr later

    Its first report, Oct 22, 4:28 PM EDT

  • Center

    First to report

    MarketWatch, Oct 21, 11:00 AM EDT

  • Right

    No report yet

    From the outlets Mantle follows

See the order the outlets reported inHide the order
  1. MarketWatchCenterOct 21, 11:00 AM EDT
  2. CNBCCenterOct 22, 2:51 PM EDT
  3. BloombergLeftOct 22, 4:28 PM EDT
  4. Financial TimesCenterOct 22, 5:37 PM EDT

Times are the ones the outlets published in their own feeds, in Eastern time. Opinion is left out.

Read next

Help someone else find the truth beneath the surface

Most people see one side of a story. Share this one, so they can see how every side is telling it and decide for themselves.

Email it

Seen a mistake? Tell us what is wrong with this page